Allen R. Chen, MD

Photos

1800 Orleans St Bldg 11TH Fl 11
Baltimore, MD 21287
Chen's primary area of research focuses on bone marrow transplantation (BMT), a highly complex and specialized aspect of pediatric oncology that, in recent years, has become an accepted form of therapy for an increasingly broad range of cancers. In addition to the myriad ways BMT is currently being utilized at Hopkins, Chen is working to refine novel approaches to the therapy and apply them to some of the toughest cases. "One hypothesis is that, in patients receiving a transplant using their own stored stem cells, we can induce an immunologic response from their own cells that mimics the graft received from a healthy donor," Chen says. "We're also excited about the ability to foster immune tolerance when the only available healthy donors aren't perfect matches for the patient."In a quest to solve some of the rarest and most troubling treatment challenges facing pediatric oncology, Chen and fellow pediatric oncologists at Hopkins have joined forces with others around North America in the Pediatric Blood and Marrow Transplant Consortium. "We're trying to develop multi-institutional studies to improve the effectiveness of BMT for cancer. The study we're working on now will help us to understand why some patients relapse in spite of BMT for acute myeloid leukemia," says Chen, who chairs the Oncology Strategy Group of this consortium.Chen also immerses himself in several Hopkins-based initiatives. Recently, he was named Chair of the Oncology Clinical Research Review Committee, a group mandated to oversee all patient-oriented research in the comprehensive cancer center to ensure it meets the center's standards of scientific merit and priority.He also chairs the Performance Improvement Committee. This multi-disciplinary group consists of physicians, nurses, and pharmacists who examine practical ways to reduce errors and improve patient outcomes. The committee recently joined forces with Hopkins' information technology professionals to apply a computerized order entry system—even to complex treatment protocols like chemotherapy."We've seen an amazing improvement; a number of potential medication errors decreased dramatically," Chen says. Currently, the committee is analyzing ways to reduce bloodstream infections in pediatric patients, which can create potentially life-threatening complications. Despite the hectic pace of Chen's professional life, he has managed to find a way to leave behind the stress of his job and bond with his own children. He and his sons began taking Kung Fu classes when his older son began middle school. He's since grown up and left for college, but Chen continues the practice as both a student and a teacher.Regardless of where Chen is, he's never too far removed from the challenges that await him at work. "Sometimes, in the wee hours of the morning, I suddenly realize why a complication has occurred," he says.
Request an Appointment
Owner verified
See a problem?

You might also like

Christine Pratilas, MD
Testing laboratories

Christine Pratilas, MD

Dr. Christine Pratilas is a pediatric medical oncologist at the Sidney Kimmel Comprehensive Cancer Center and Associate Professor of Oncology, Pediatrics & Cellular and Molecular Medicine at the Johns Hopkins University School of Medicine. She joined the Hopkins pediatric sarcoma team in 2014. Dr. Pratilas received her undergraduate degree in Biology from Drew University in New Jersey and her medical degree from UMDNJ - Robert Wood Johnson Medical School (now Rutgers University), where she also completed her internship and residency from 1999 to 2002. From 2002 to 2005 she was a fellow in hematology and oncology in the Memorial Sloan Kettering Cancer Center (MSKCC) Department of Pediatrics, and in the Department of Pediatric Hematology and Oncology at New York Weill Cornell Medical Center. She was a postdoctoral research fellow in Dr. Neal Rosen’s Molecular Oncogenesis Laboratory at MSKCC. From 2006 to 2014 she was attending in Pediatric Oncology at MSKCC, specializing in developmental therapeutics & sarcoma. She has been the director of the pediatric sarcoma program at Hopkins since 2018. Dr. Pratilas focuses her research on cancer-associated pathways and signal transduction, which involves figuring out how a cell’s internal molecular pathways work, and how those pathways can be molecularly controlled. This knowledge is the basis for developing promising new molecularly targeted cancer therapies, which is the focus of Dr. Pratilas’s research. Among her important scientific contributions is advancing our understanding of how certain proteins that can be mutated in cancer, known as RAF kinases (specifically BRAF), affect a cancer cell’s behavior. The research in Dr. Pratilas' laboratory is focused on RAS signal transduction pathways, concentrating on pediatric sarcomas such as rhabdomyosarcoma and malignant peripheral nerve sheath tumors, in order to develop novel therapeutics for children with these tumors.
Heather Symons, MD
Internal medicine practitioners

Heather Symons, MD

In her first decade as a pediatric oncologist, Dr. Symons already has shown an impressive ability to juggle multiple research projects, in addition to caring for patients.One of Dr. Symons' research pursuits focuses on using a novel immunotherapy approach to treating both solid tumors and hematologic (blood-borne) malignancies. The basis of her work stems from the theory that cancer patients' immune systems should recognize tumor cells as foreign and destroy them. This doesn't happen, theorizes Dr. Symons, because the immune system attacks only those cells it perceives as dangerous—not cancer cells, which it sees simply as foreign. That's where her research comes into play.Evaluating an experimental therapy, Dr. Symons is pairing donor lymphocytes (white blood cells that activate the body's immune system) with chemotherapy to determine if this combination will "awaken" patients' immune systems to the danger of existing cancer cells and, in turn, elicit an immune response.In a separate yet equally compelling research endeavor, Dr. Symons is working to increase the availability of donors for children whose cancer requires bone marrow transplants (BMTs) as a potentially lifesaving treatment. "It can be challenging to find a 'matched' donor," says Dr. Symons, who explains that only about 40 percent of patients who require a BMT find a matched donor. "Sometimes, we don't have the benefit of time, because remissions can be short-lived. But almost all patients have a half-matched donor: a parent, sibling, or child," adds Dr. Symons, who is examining ways to reduce BMT-related complications ordinarily associated with half-matched donors after ablative (high dose) chemotherapy."Like anything else that's new, it will take some time to prove that this is a feasible option that's safe," she says. But she's optimistic. "It has the potential to revolutionize BMT." Dr. Symons knows it's worth the wait. "Seeing the research I do in the lab translate into clinical trials, then seeing patients in these trials survive long term, is incredibly rewarding," she says.
United StatesMarylandBaltimoreAllen R. Chen, MD

Partial Data by Infogroup (c) 2025. All rights reserved.

Yext

Partial Data by Foursquare.